Context Therapeutics Past Earnings Performance
Past criteria checks 0/6
Context Therapeutics's earnings have been declining at an average annual rate of -39.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-39.7%
Earnings growth rate
55.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -36.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Revenue & Expenses Breakdown
How Context Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -30 | 7 | 25 |
| 30 Jun 24 | 0 | -19 | 7 | 13 |
| 31 Mar 24 | 0 | -21 | 7 | 15 |
| 31 Dec 23 | 0 | -24 | 7 | 18 |
| 30 Sep 23 | 0 | -21 | 7 | 15 |
| 30 Jun 23 | 0 | -19 | 8 | 12 |
| 31 Mar 23 | 0 | -18 | 8 | 10 |
| 31 Dec 22 | 0 | -15 | 8 | 7 |
| 30 Sep 22 | 0 | -14 | 8 | 6 |
| 30 Jun 22 | 0 | -12 | 7 | 5 |
| 31 Mar 22 | 0 | -13 | 5 | 5 |
| 31 Dec 21 | 0 | -10 | 4 | 4 |
| 30 Sep 21 | 0 | -8 | 2 | 3 |
| 30 Jun 21 | 0 | -7 | 1 | 3 |
| 31 Mar 21 | 0 | -1 | 1 | 2 |
| 31 Dec 20 | 0 | 1 | 1 | 2 |
Quality Earnings: CNTX is currently unprofitable.
Growing Profit Margin: CNTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNTX is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare CNTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CNTX has a negative Return on Equity (-35.96%), as it is currently unprofitable.